Finally, we identified a population with KRAS‐mutated metastatic tumors that received treatment with EGFR antibodies prior to biopsy of metastatic site, based on a diagnosis of KRAS wild‐type in CRC primary performed outside our institution. The gene discussed is EGFR; the disease is colorectal carcinoma.